Down syndrome, beta-amyloid and neuroimaging

Area of Science:

• Neuroscience and Genetics
• Alzheimer's Disease Research
• Down Syndrome Studies

Background:

• Down syndrome (DS) invariably leads to Alzheimer's disease (AD) pathology due to genetic factors.
• Amyloid-beta (Aβ) deposition is a hallmark of AD pathogenesis, particularly relevant in DS.
• Understanding Aβ's role in DS is crucial for developing targeted therapeutic strategies.

Purpose of the Study:

• To review the role of Aβ in Alzheimer's disease (AD) pathogenesis in Down syndrome (DS).
• To summarize current in vivo imaging approaches for detecting Aβ in the brain.
• To present unique case studies illustrating Aβ pathology in specific genetic contexts within DS.

Main Methods:

• Literature review focusing on Aβ deposition, posttranslational modifications, and biofluid detection in DS.
• Summary of in vivo brain imaging techniques for Aβ, including Positron Emission Tomography (PET) and specific ligands (e.g., Pittsburgh Compound B, Florbetapir, FDDNP).
• Analysis of case studies involving partial trisomy 21 and mosaic trisomy 21 in early-onset AD patients.

Main Results:

• Aβ deposits characteristically with age in individuals with DS.
• Various posttranslational modifications of Aβ can occur, influencing its detection.
• In vivo imaging techniques effectively detect Aβ in the brain, aiding in understanding its accumulation patterns.

Conclusions:

• Significant progress has been made in characterizing Aβ pathology and its age of onset in DS.
• In vivo Aβ imaging provides valuable insights into AD pathogenesis in DS.
• An ongoing clinical trial targeting Aβ in DS holds promise for potential clinical benefits.